Who Owns Integra LifeSciences Company?

Integra LifeSciences Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Integra LifeSciences?

Integra LifeSciences, a medical technology firm, began its journey in 1989, founded by Richard Caruso. Its IPO in 1995 transitioned it to public ownership, attracting a wider investor base.

The company focuses on surgical implants and medical instruments, aiming to enhance patient recovery through tissue regeneration and advanced surgical tools. Its product range includes innovations like Integra LifeSciences BCG Matrix.

As of December 31, 2023, Integra LifeSciences had a global workforce of approximately 3,946 employees. For the fiscal year 2024, the company reported revenues totaling $1,610.5 million, marking a 4.5% increase compared to the previous year.

Integra LifeSciences was founded in 1989 by Richard Ernest Caruso, who initiated the company in the Philadelphia, Pennsylvania, area. Caruso's educational background includes an accounting degree and an advanced business degree, followed by a career in auditing. The company's establishment was marked by licensing artificial skin technology and acquiring a subsidiary from another company.

Founder's Vision

Richard Ernest Caruso founded Integra LifeSciences in 1989. His vision centered on regenerative technologies for cartilage and peripheral nerves.

Early Technological Foundation

The company's early development was built upon licensing artificial skin technology from Harvard-MIT. It also involved acquiring Colla-tec, a subsidiary of Marion Laboratories.

Initial Growth Strategy

Early strategic moves included acquiring the Wound Care Division of Marion Merrell Dow in 1991. These acquisitions were key to shaping the company's focus.

Public Offering

Integra LifeSciences became a publicly traded company in 1995 through a reverse merger. A subsequent stock offering in early 1996 raised $35 million.

Funding for Expansion

The public offering was crucial for securing capital needed for the company's expansion and development initiatives. This provided essential resources for growth.

Early Ownership Details

Specific details regarding initial equity splits or founder shareholdings are not publicly disclosed. The early focus was on technological development and market entry.

While the precise initial ownership structure and equity distribution among founders and early investors are not publicly detailed, the company's formative years were characterized by significant investment in regenerative technologies. Integra LifeSciences' journey to becoming a publicly traded entity involved a reverse merger with Telios Pharmaceuticals in 1995, followed by a public offering that secured $35 million in early 1996. This capital infusion was vital for the company's subsequent growth and development, underscoring the strategic financial maneuvers undertaken by the founding team to realize their vision for advancing medical technologies. For a deeper understanding of the company's historical trajectory, you can refer to the Brief History of Integra LifeSciences.

Key Milestones in Early Ownership

The early ownership and development of Integra LifeSciences were shaped by strategic licensing, acquisitions, and a pivotal public offering.

• Founded in 1989 by Richard Ernest Caruso.
• Licensed artificial skin technology from Harvard-MIT.
• Acquired Colla-tec from Marion Laboratories.
• Acquired the Wound Care Division of Marion Merrell Dow in 1991.
• Went public via reverse merger with Telios Pharmaceuticals in 1995.
• Raised $35 million through a stock offering in early 1996.

Integra LifeSciences SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Integra LifeSciences embarked on its journey as a publicly traded entity on August 16, 1995, listing on the NASDAQ under the ticker symbol IART. This transition marked a significant step in its ownership evolution, moving from private to public hands. The company has since undertaken various capital-raising activities, including a stock offering in May 2018 to manage its debt structure.

The ownership landscape of Integra LifeSciences is predominantly shaped by institutional investors, indicating a strong professional backing. As of July 31, 2025, these large entities held a substantial 95.11% of the company's stock, with another report from August 2, 2025, placing this figure at 84.78%. This concentration of ownership among institutional shareholders suggests a significant influence on the company's strategic direction and governance. Insiders hold a smaller portion, amounting to 3.24% as of July 31, 2025, while public companies and individual investors collectively own 12.60%.

Key Institutional Holders

Major institutional investors play a crucial role in Integra LifeSciences' shareholder base. Their significant holdings underscore a broad professional confidence in the company's prospects.

• BlackRock, Inc. is a top institutional investor, holding 10,739,043 shares as of March 31, 2025.
• Vanguard Group Inc. is another substantial shareholder, with 7,516,628 shares as of the same date.
• Other notable institutional investors include Morgan Stanley, Rubric Capital Management LP, and Invesco Ltd.
• The presence of these large funds highlights the widespread professional investment in Integra LifeSciences, influencing its corporate structure and ownership details. Understanding the Revenue Streams & Business Model of Integra LifeSciences can provide further insight into why these institutions are invested.

Integra LifeSciences PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Integra LifeSciences is responsible for the company's strategic direction and governance. Key leadership changes, such as the appointment of Mojdeh Poul as President and CEO effective January 6, 2025, underscore the board's role in succession planning.

The voting power within Integra LifeSciences generally adheres to a one-share-one-vote principle, a standard practice for publicly traded entities. As of February 24, 2025, the company had 77,218,920 common shares outstanding. While specific details on founder shares or dual-class structures are not prominent, the significant institutional ownership, standing at 84.78% as of August 2, 2025, indicates that large institutional investors collectively wield considerable voting influence. Publicly available information from 2024-2025 does not highlight major proxy battles or activist campaigns, suggesting a period of stable corporate governance, though institutional investors can still impact decisions through direct engagement with the board and management. Understanding these dynamics is crucial for comprehending Integra LifeSciences ownership and its implications for investors, especially when considering the broader Competitors Landscape of Integra LifeSciences.

Understanding Voting Power

Voting power in publicly traded companies like Integra LifeSciences is typically tied to share ownership. Institutional investors often hold significant blocks of shares, giving them substantial influence.

• One-share-one-vote principle is common.
• Institutional ownership was 84.78% as of August 2, 2025.
• Total outstanding common shares were 77,218,920 as of February 24, 2025.
• Board composition and leadership changes impact governance.

Integra LifeSciences Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Integra LifeSciences has seen significant leadership transitions and evolving financial performance over the past few years. The company appointed Mojdeh Poul as its new President and CEO in early 2025, marking a key leadership change. Ownership trends indicate a strong presence of institutional investors, reflecting confidence in the company's direction.

Institutional investors maintain a substantial stake in Integra LifeSciences, with ownership figures hovering around 84.78% as of August 2, 2025, and 95.11% as of July 31, 2025. This high level of institutional backing suggests continued investor confidence. Recent SEC filings show ongoing trading activity by these entities, with some increasing their holdings, such as Quadrant Capital Group LLC's significant stake growth in late 2024. Strategic acquisitions, like the Acclarent purchase, continue to influence revenue growth, while the company prioritizes enhancements to its quality systems and supply chain reliability.

Leadership Transition

Mojdeh Poul assumed the role of President and CEO on January 6, 2025. This leadership change is a significant development for the company's strategic direction.

Institutional Ownership Trends

Institutional investors hold a dominant share of Integra LifeSciences stock, exceeding 84% in mid-2025. This indicates strong backing from major financial entities.

Financial Performance Highlights

The company reported full-year 2024 revenues of $1,610.5 million. While facing some organic sales challenges in early 2025, full-year guidance remains robust.

Strategic Focus Areas

Integra LifeSciences is concentrating on improving its quality systems and supply chain consistency. These operational improvements are crucial for sustained growth and investor sentiment.

Integra LifeSciences Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔